tweenvest

Cosmo N.V. (SWX: CMHC)

Health Care · Pharmaceuticals · IE

CHF55.00

-0.90% today · -16.8% 1Y

Public summary
A free snapshot of Cosmo N.V., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Cosmo N.V. (SWX: CMHC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.12B and employs 3,245 people.

Over the last twelve months the share price has lost 16.8%, trading between 49.00 and 129.40.

Tweenvest scores Cosmo N.V. across four factors: quality 67/100, value 71/100, growth 14/100, dividend 68/100. Its strongest factor is value.

CMHC price history

Nov 21, 2025 · 67.10Weekly closes 51.40 – 119.20Nov 19, 2026 · 55.00

Key figures

Market cap
$1.12B
Revenue (TTM)
$117.32M
P/E
-152.23
EPS
-0.35
Dividend yield
3.44%
Beta (5Y)
1.48
52-week high
CHF129.40
52-week low
CHF49.00
Avg volume (3M)
—
Shares outstanding
17.19M
Employees
3,245
Next earnings
—

About Cosmo N.V.

Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

ISIN
NL0011832936
Founded
1997
Listed since
Mar 12, 2007
Exchange
SIX Swiss Exchange
Currency
CHF
CompanyMarket capPriceDay
Lotus Pharmaceutical Co., Ltd.TWSE: 1795$1.16BNT$141.50-9.29%
North China Pharmaceutical Company.LtdSHSE: 600812$1.15BCN¥4.46-0.89%
Tianjin Ringpu Bio-Technology Co.,Ltd.SZSE: 300119$1.13BCN¥16.54-0.42%
MedinCell S.A.ENXTPA: MEDCL$1.13B€28.48-1.18%
Viyash Scientific LimitedBSE: 512529$1.11BRs236.25-7.39%
Vetoquinol SAENXTPA: VETO$1.10B€86.30-0.12%
Guilin Sanjin Pharmaceutical Co., Ltd.SZSE: 002275$1.10BCN¥12.46-3.56%
ST Pharm Co.,Ltd.KOSDAQ: A237690$1.10B₩70,200.00-1.13%

Browse every Pharmaceuticals company →